Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

Monash IVF (ASX:MVF) Falls 6% on Monday – Why Monash IVF Said No to Buyout Offer

Monash IVF Group Ltd (ASX:MVF) is one of Australia’s leading providers of assisted reproductive services, operating fertility clinics across Australia and internationally. The company plays a key role in the healthcare sector, particularly in fertility treatment and reproductive medicine.

Sonal Goyal | 20 April 2026

4DMedical (ASX:4DX) on Investor’s Radar on Monday. Here’s Why.

4DMedical (ASX:4DX) shares traded at AUD 5.790, down AUD 0.049 or 0.856%, on 20 April 2026, on volume of 6,559,404 shares. The bid-offer spread at the time of capture was AUD 5.780 to AUD 5.790 and market capitalisation was AUD 3.44 billion. The marginal …

Sonal Goyal | 20 April 2026

Ramsay Health Care (ASX: RHC) Edges Higher as Hospital Operator Weighs European Options and Domestic Reform

The S&P/ASX 200 Health Care Index itself was narrowly higher, up 0.02 per cent at 28,094.00 points. The Ramsay share price move reflects both defensive sector flows and ongoing news flow around private hospital funding agreements between operators and private health insurers in Australia.

Aditi Sarkar | 17 April 2026

Sigma Healthcare (ASX: SIG) Tops ASX 200 Health Care Gainers as Chemist Warehouse Combination Reshapes Pharmacy Distribution

The Sigma share price performance reflects the unique position SIG now holds in Australian pharmacy: a combined wholesaling, franchising and owner-operator ecosystem spanning community pharmacy, consumer health, and private-label products. With the integration underway and regulatory proceedings well behind the combined entity, investors are …

Aditi Sarkar | 17 April 2026

Telix Pharmaceuticals (ASX: TLX) Advances as Radiopharmaceutical Pipeline and Illuccix Sales Drive Momentum

Telix is in focus thanks to its commercial-stage radiopharmaceutical business, anchored by the prostate cancer imaging agent Illuccix and an extensive pipeline of next-generation targeted radionuclide therapies across prostate, renal and glioblastoma indications. The company has become a notable global radiopharmaceutical operator with operations …

Aditi Sarkar | 17 April 2026

Neuren Pharmaceuticals (ASX: NEU) Drifts Lower as Rett Syndrome Drug Rollout and Pipeline Catalysts Dominate Investor Focus

Neuren Pharmaceuticals Limited (ASX: NEU) slipped 0.96 per cent to $12.36 on 17 April 2026, placing the clinical-stage biopharmaceutical company among the notable decliners on the S&P/ASX 200 Health Care Index at the open. While the broader XHJ index crept higher by 0.02 per …

Aditi Sarkar | 17 April 2026

Mesoblast (ASX: MSB) Steady at $2.24 as Ryoncil Commercial Launch Anchors Investor Narrative

Mesoblast Limited (ASX: MSB) was unchanged at $2.24 on 17 April 2026 in early ASX trade, with the stock appearing at the bottom of the S&P/ASX 200 Health Care Index top movers list for the session with a flat intraday change. The broader XHJ …

Aditi Sarkar | 17 April 2026

Cochlear (ASX: COH) Eases as Global Hearing Implant Leader Navigates Product Cycle and Services Growth

Cochlear Limited (ASX: COH) slipped 0.38 per cent to $169.15 on 17 April 2026 in early ASX trade, making the global hearing implant leader one of the modest decliners in the S&P/ASX 200 Health Care Index on the day. The broader XHJ index was …

Aditi Sarkar | 17 April 2026

Ansell (ASX: ANN) Steady as Global Protective Solutions Group Targets Post-Restructuring Margin Recovery

Ansell Limited (ASX: ANN) eased 0.18 per cent to $27.67 on 17 April 2026, little changed on a day when the broader S&P/ASX 200 Health Care Index inched up 0.02 per cent to 28,094.00 points. Ansell's movement was modest and consistent with normal trading …

Aditi Sarkar | 17 April 2026

Proteomics International (ASX: PIQ) Restructures to Accelerate Diagnostics Commercialisation

Proteomics International Laboratories Ltd (ASX:PIQ) has announced a series of organisational and leadership changes as part of an ongoing strategic review aimed at repositioning the company toward a commercially focused diagnostics model. The update reflects a structural shift in operations, as the company moves …

Aditi Sarkar | 17 April 2026
Support

Hi! How can we help you today?

Loading…